Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic®.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Novo Nordisk said the Food and ... failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday. The approval makes Ozempic the most broadly indicated GLP-1 drug ...

Novo Nordisk already has broad FDA approvals ... 2 diabetes who also have atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD). It would become the first add-on ...

Ozempic will become the first and only GLP-1 receptor agonist to show lowering of risk of kidney disease progression in adults with Type 2 diabetes and chronic kidney disease.” Novo Nordisk has ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Novo Nordisk A/S NVO on Saturday presented ... events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD). The SOUL trial achieved its primary ...

Novo Nordisk on Saturday ... the cardiovascular rather than kidney benefits of the pill, Gough said. Ozempic is already approved to treat chronic kidney disease in diabetes patients.